Reuters: Health
U.S. regulators delayed a decision on Roche's spinal muscular atrophy drug risdiplam, the Swiss drugmaker said on Tuesday, after the company submitted more data in February on the medicine against the genetic muscle-wasting disease.
U.S. regulators delay decision on Roche SMA drug risdiplam to Aug. 24
U.S. regulators delay decision on Roche SMA drug risdiplam to Aug. 24
Reuters: Health
U.S. regulators delayed a decision on Roche's spinal muscular atrophy drug risdiplam, the Swiss drugmaker said on Tuesday, after the company submitted more data in February on the medicine against the genetic muscle-wasting disease.
Reuters: Health
U.S. regulators delayed a decision on Roche's spinal muscular atrophy drug risdiplam, the Swiss drugmaker said on Tuesday, after the company submitted more data in February on the medicine against the genetic muscle-wasting disease.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment